Survanta Suspension (Intratracheal)

Phospholipids
25mg/ml
ABBVIE Inc.
Pack size 8ml Vial
Dispensing mode POM
Source USA
AgentCITY MEDICAL STORE
Retail Price 2092.50 AED

Indications

Survanta Suspension (Intratracheal) is used for: Resp distress syndrome (RDS) in premature infants.

Adult Dose

Child Dose

Prevention in premature infant <1250 g birthwt or w/ evidence of surfactant deficiency Preferably w/in 15 mins of birth. Rescue Preferably by 8 hr of age. 4 mL/kg birth wt(100 mg of phospholipids/kg birth wt) intratracheally up to 4 doses in 1st 48 hr. Doses should not be given more frequently than 6 hrly. To be administered as soon as possible.

Renal Dose

Administration

Contra Indications

None known.

Precautions

Infants <600 g birth wt. For intratracheal use only.

Pregnancy-Lactation

Interactions

Adverse Effects

Side effects of Phospholipids : Transient bradycardia. O2 desaturation, endotracheal tube reflux & blockage, pallor, vasoconstriction, hypotension, HTN, hypocarbia, hypercarbia & apnea.

Mechanism of Action

Natural bovine pulmonary surfactant; replaces deficient endogenous lung surfactant in neonates with respiratory distress syndrome. Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between alveolar surfaces and air.

Note

Survanta 25mg/ml Suspension (Intratracheal) manufactured by ABBVIE Inc.. Its generic name is Phospholipids. Survanta is availble in United Arab Emirates. Farmaco UAE drug index information on Survanta Suspension (Intratracheal) is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Phospholipids :